Abstract
Background COVID-19 is a global disease caused by the Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2). Patients with a severe or critical illness can develop respiratory and cardiovascular complications. This study aimed to describe a Latin American and Caribbean (LA&C) population with COVID-19 to provide information related to this disease, in-hospital cardiovascular complications and in-hospital mortality.
Methods The CARDIO COVID-19-20 Registry is an observational, multicenter, ambispective, and hospital-based registry of patients with confirmed COVID-19 infection that required in-hospital treatment in LAC. Enrollment of patients started on May 01, 2020, and ended on June 30, 2021.
Results The CARDIO COVID-19-20 Registry included 3260 patients from 44 institutions of 14 LA&C countries. 63.2% patients were male and median age was 61.0 years old. Most common comorbidities were overweight/obesity (49.7%), hypertension (49.0%), and diabetes mellitus (26.7%). Most frequent cardiovascular complications were cardiac arrhythmia (9.1%), decompensated heart failure (8.5%), and pulmonary embolism (3.9%). 53.5% of patients were admitted to Intensive Care Unit (ICU), and median length of stay at the ICU was 10.0 days. Support required in ICU included invasive mechanical ventilation (34.2%), vasopressors (27.6%), inotropics (10.3%) and vasodilators (3.7%). Rehospitalization after 30-day post discharge was 7.3%. In-hospital mortality and 30-day post discharge was 25.5% and 2.6%, respectively.
Conclusions The LA&C population with COVID-19 patients and hospitalization, has a considerable burden of cardiovascular diseases related to a worse prognosis. It is necessary to carry out a more specific analysis to determine risk factors for cardiovascular outcome.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Ethics committee/IRB of Fundación Valle del Lili gave ethical approval for this work
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
The authors confirm that the data supporting the findings of this study are available within the article and its supplementary materials.
